Home - Products - Others - Other Targets - (25R)-12α-Hydroxyspirost-4-en-3-one

(25R)-12α-Hydroxyspirost-4-en-3-one

CAS No. 50888-50-1

(25R)-12α-Hydroxyspirost-4-en-3-one( ——— )

Catalog No. M38119 CAS No. 50888-50-1

(25R)-12α-Hydroxyspirost-4-en-3-one is a minor metabolite produced by the action of Nocardia globerula on Hecogenin.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    (25R)-12α-Hydroxyspirost-4-en-3-one
  • Note
    Research use only, not for human use.
  • Brief Description
    (25R)-12α-Hydroxyspirost-4-en-3-one is a minor metabolite produced by the action of Nocardia globerula on Hecogenin.
  • Description
    (25R)-12α-Hydroxyspirost-4-en-3-one is a minor metabolite produced by the action of Nocardia globerula on Hecogenin.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    50888-50-1
  • Formula Weight
    428.6
  • Molecular Formula
    C27H40O4
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Howe R, et al. Microbial modification of diosgenin and hecogenin. J Chem Soc Perkin 1. 1973;17:1940-3.?
molnova catalog
related products
  • Randaiol

    Randaiol is a natural product from Magnolia hypoleuca.

  • Flavanomarein

    Flavanomarein demonstrates potent antioxidative property, including free radical scavenging activity, inhibition of lipid peroxidation, as well as lipid-lowering effects in human HepG2 hepatocellular carcinoma cells treated with free fatty acids (FFAs).

  • Linaprazan glurate

    Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate can be used in studies about gastrointestinal inflammatory diseases and peptic ulcer diseases.